ATE290866T1 - Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten - Google Patents

Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Info

Publication number
ATE290866T1
ATE290866T1 AT99965071T AT99965071T ATE290866T1 AT E290866 T1 ATE290866 T1 AT E290866T1 AT 99965071 T AT99965071 T AT 99965071T AT 99965071 T AT99965071 T AT 99965071T AT E290866 T1 ATE290866 T1 AT E290866T1
Authority
AT
Austria
Prior art keywords
treatment
neurotrophic factor
ophthalmic diseases
factor stimulators
neurodegenerative
Prior art date
Application number
AT99965071T
Other languages
English (en)
Inventor
Iok-Hou Pang
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Application granted granted Critical
Publication of ATE290866T1 publication Critical patent/ATE290866T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
AT99965071T 1998-12-03 1999-12-01 Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten ATE290866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11098398P 1998-12-03 1998-12-03
PCT/US1999/028385 WO2000032197A1 (en) 1998-12-03 1999-12-01 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE290866T1 true ATE290866T1 (de) 2005-04-15

Family

ID=22335984

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965071T ATE290866T1 (de) 1998-12-03 1999-12-01 Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Country Status (16)

Country Link
EP (1) EP1135134B1 (de)
JP (1) JP2002531405A (de)
KR (1) KR100688137B1 (de)
CN (1) CN1325308A (de)
AR (1) AR022685A1 (de)
AT (1) ATE290866T1 (de)
AU (1) AU769290B2 (de)
BR (1) BR9915803A (de)
CA (1) CA2353527C (de)
DE (1) DE69924284T2 (de)
ES (1) ES2237196T3 (de)
HK (1) HK1038510B (de)
PT (1) PT1135134E (de)
TW (1) TWI246421B (de)
WO (1) WO2000032197A1 (de)
ZA (1) ZA200102714B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385931T3 (es) * 2000-07-07 2012-08-03 Spectrum Pharmaceuticals, Inc. MÉTODOS PARA EL TRATAMIENTO DE NEUROPATíA PERIFÉRICA INDUCIDA POR UNA ENFERMEDAD Y AFECCIONES RELACIONADAS.
US20020156277A1 (en) * 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
BR0212151A (pt) * 2001-08-29 2004-08-24 Alcon Inc Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas
EP1666068A4 (de) * 2003-09-24 2010-08-04 Santen Pharmaceutical Co Ltd Mittel zur behandlung von augenerkrankungen mit verletzungen des sehnervs
CA2589001A1 (en) * 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for neuropathic pain
EP1754474A1 (de) * 2005-02-02 2007-02-21 Eucro European Contract Research GmbH & Co. KG Verwendung von S-Clenbuterol
US20090082455A1 (en) 2005-03-15 2009-03-26 Ono Pharmaceutical Co. Lted Therapeutic agent for ophthalmic disease
DK2605769T3 (en) 2010-08-16 2016-10-24 Santhera Pharmaceuticals (Schweiz) Ag Benzoquinonderivater for the treatment of mitochondrial diseases of the eye
EP2911656B1 (de) * 2012-10-23 2020-12-02 Nicox SA Chinonbasierte stickoxiddonatorenverbindungen zur ophthalmischen verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (ja) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd 糖尿病性合併症の予防・治療剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
CA2265743A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
JPH10218787A (ja) * 1997-02-06 1998-08-18 Akio Okamoto 神経栄養因子による眼科用組成物

Also Published As

Publication number Publication date
EP1135134A1 (de) 2001-09-26
KR20010075055A (ko) 2001-08-09
EP1135134B1 (de) 2005-03-16
ZA200102714B (en) 2002-06-03
AR022685A1 (es) 2002-09-04
CN1325308A (zh) 2001-12-05
HK1038510A1 (en) 2002-03-22
CA2353527A1 (en) 2000-06-08
HK1038510B (en) 2005-05-20
TWI246421B (en) 2006-01-01
BR9915803A (pt) 2001-08-21
ES2237196T3 (es) 2005-07-16
JP2002531405A (ja) 2002-09-24
KR100688137B1 (ko) 2007-03-09
AU769290B2 (en) 2004-01-22
WO2000032197A1 (en) 2000-06-08
DE69924284T2 (de) 2005-08-04
PT1135134E (pt) 2005-05-31
AU3106600A (en) 2000-06-19
DE69924284D1 (de) 2005-04-21
CA2353527C (en) 2007-11-06

Similar Documents

Publication Publication Date Title
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE59711321D1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
ATE433323T1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
ATE285764T1 (de) Rivastigmine zur behandlung von augenerkrankungen
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1135134

Country of ref document: EP